Retinitis pigmentosa: why night vision and contrast fade first

If you have been told you have retinitis pigmentosa, or you are reading up on a relative's diagnosis, the first useful thing to know is that the name describes a pattern, not a single disease. Retinitis pigmentosa (RP) is a family of inherited retinal conditions that share a characteristic order of symptoms: night vision tends to go first, side vision narrows over years, and sharp central vision is often the last thing to change. Understanding why that order happens - and where a simple functional measure like contrast sensitivity fits into it - can make the condition feel less like a mystery and more like something you can track and talk about clearly with the people caring for your eyes.

The short version: RP damages the retina's rod photoreceptors first, which is why difficulty seeing in dim light and slow dark adaptation are usually the earliest symptoms. Contrast sensitivity - how faint a pattern you can still make out - can drop even while the eye chart still reads well, so it is a helpful functional signal to notice and track over time. It is not a diagnosis. Diagnosing RP takes a retinal specialist and clinical tests: electroretinography (ERG), visual field testing, retinal imaging (OCT), and often genetic testing.

What retinitis pigmentosa actually is

Your retina is lined with two kinds of light-detecting cells. Cones handle bright light, fine detail, and color, and they are packed most densely in the central macula. Rods handle dim light; they are far more numerous than cones, they are spread across the mid-periphery of the retina, and they are exquisitely sensitive - a well-adapted rod can respond to a single photon. In retinitis pigmentosa, it is the rods that fail first.

RP is not one condition but a group of inherited retinal dystrophies. Taken together they affect on the order of 1 in 4,000 people, which makes RP one of the more common causes of inherited blindness worldwide. What unites the group is the sequence Hartong, Berson, and Dryja describe in their widely cited review: patients typically lose night vision in adolescence, side vision in young adulthood, and central vision later in life, as rod photoreceptors degenerate first and cones follow.¹

The genetics are strikingly varied. Mutations in dozens of different genes can produce an RP phenotype - the outward pattern of the disease - and well over 100 genes have been implicated across the broader family of inherited retinal degenerations. The condition can be inherited in autosomal dominant, autosomal recessive, or X-linked patterns - the different ways a faulty gene can be passed down a family - or appear with no clear family history at all.¹ Most of the genes involved encode proteins that rods depend on: components of the phototransduction cascade, the visual cycle that recycles the light-sensitive pigment, or the structural machinery of the photoreceptor. When one of those proteins is faulty, rods are placed under chronic stress and gradually die, and the cones that share the neighborhood are eventually affected too. This genetic heterogeneity is a large part of why the age of onset and the pace of change differ so much from one person to the next - and why the disease is careful work to characterize rather than something to self-assess.

Why night vision and dark adaptation go early

Because rods are the low-light system, damaging them shows up first exactly where rods do their work: in the dark. The earliest symptom of RP is usually nyctalopia, or night blindness - difficulty seeing in dim conditions and a longer, less complete adjustment when moving from bright light into darkness.

That adjustment has a name: dark adaptation. Walk from a sunlit street into a dim room and for the first several minutes you can barely see; over the next twenty minutes or so your sensitivity climbs enormously as your rods regenerate their pigment. We walk through that recovery curve in detail in the dark-adaptation post. In RP, the rod portion of that curve is blunted. Rods recover their sensitivity slowly and incompletely, so the final threshold - the faintest light a fully dark-adapted eye can detect - is raised, sometimes by two or more log units (a hundredfold or greater increase in the light needed to see). A review of dark adaptometry across retinal diseases describes this pattern in RP: delayed rod-mediated recovery and markedly elevated dark-adapted thresholds, reflecting rods that can no longer reset efficiently.²

Lived, that feels like taking much longer than other people to find your way in a dark cinema, hesitating on unlit stairs, or losing confidence driving at dusk when neither daylight nor headlights are carrying the scene. These are subjective experiences, but they map onto a real, measurable change in rod function. Clinicians can quantify the dark-adaptation curve with dedicated instruments; our companion piece on the AdaptDx patient experience describes what one of those sessions is actually like. The important nuance is that noticing slow dark adaptation is a functional signal - a reason to get examined - and not a diagnosis of RP, because aging, vitamin A deficiency, and other retinal conditions can slow the same curve.

The slowly narrowing field of view

As rod loss spreads across the mid-peripheral retina, the second hallmark of RP appears: a gradual constriction of the visual field. Because rods sit in a band around the central macula, their loss first carves out a ring-shaped blind zone in the mid-periphery - a partial ring scotoma - which over years widens both inward and outward. The result is the phenomenon often described as tunnel vision: a shrinking island of usable field, with the central macula frequently preserved until late.

This is why RP can be so easy to underestimate from the outside, and even from the inside. Because the central macula is doing the reading, a person can retain 20/20 acuity on the eye chart while their usable field has narrowed dramatically - enough to make crowded sidewalks, sports, and driving genuinely hazardous. The eye chart is measuring the very last part of vision RP tends to touch. That mismatch between a good acuity number and a shrinking real-world field is one of the reasons a single sharpness measurement is a poor summary of how someone actually sees.

The name of the disease comes from what an eye doctor may see on examination as this progresses: clumps of migrated retinal pigment in the mid-periphery, classically shaped like bone spicules, alongside narrowed retinal blood vessels and a pale optic disc. Those signs, though, are things a clinician observes with the retina in view - not something you can check yourself.

Where contrast sensitivity fits

Between "sharp central vision" and "shrinking field" sits a third dimension of sight that often gets overlooked: contrast sensitivity - the ability to distinguish an object from its background when the difference between them is faint. Visual acuity asks how small a high-contrast letter you can identify. Contrast sensitivity asks how faint a pattern you can detect at all. They are related but distinct, and RP can pull them apart.

The evidence for this goes back decades. Using grating tests, Lindberg and colleagues found that RP patients whose Snellen acuity was still relatively good (6/12, or 20/40, or better) nonetheless showed substantially reduced contrast sensitivity, especially at higher spatial frequencies - the fine-detail end of the range.³ More recent work using a modern computer-based contrast-sensitivity test in patients with genetically confirmed inherited retinal degenerations reached a compatible conclusion: contrast sensitivity was significantly diminished across the spatial frequencies tested, even in eyes that still measured 20/40 or better on a standard acuity chart.⁴ In other words, contrast can be an early casualty while acuity holds.

Practically, that is why contrast sensitivity is worth paying attention to. It captures something the eye chart misses, and it tends to line up with the daily complaints RP patients actually report - washed-out vision in dim or low-contrast settings, difficulty in fog or rain, a sense that the world looks flatter than it used to. Our post on seeing in low light and low contrast covers why poor lighting compounds these effects. Because contrast sensitivity can be measured repeatedly and cheaply, it also lends itself to tracking a functional signal over time - the kind of change-over-months information that is often more informative than any single reading.

None of that makes a contrast test diagnostic. A reduced result is consistent with many conditions and with nothing serious at all; it is a prompt to get examined, not an answer. It is also not a substitute for the tests that actually characterize rod and cone function.

What the clinical workup looks like

Diagnosing RP - and distinguishing it from the many conditions that can mimic parts of its picture - is careful clinical work. A retinal specialist typically draws on several complementary tests, each looking at a different layer of the problem.

Electroretinography (ERG) records the electrical response of the retina to flashes of light and can separate rod-driven from cone-driven signals. In RP the rod responses are characteristically reduced and delayed, often early and often before symptoms are severe, which makes the ERG a cornerstone of diagnosis. Visual field testing (perimetry) maps the extent of the constriction directly, quantifying the ring scotoma and tracking it over time. Optical coherence tomography (OCT) produces cross-sectional images of the retinal layers, showing the thinning of the photoreceptor layer and the state of the central macula. And genetic testing increasingly rounds out the picture: identifying the causative gene can confirm the diagnosis, clarify the inheritance pattern for family members, refine what to expect, and - importantly, in an era of emerging gene-directed therapies and clinical trials - determine eligibility for treatments tied to specific mutations.⁵

Against that battery of tests, where does a functional measure like contrast sensitivity sit? Alongside, not instead of. Clinical tests like ERG and OCT reveal the underlying biology with a precision no home tool can approach, but they are point-in-time snapshots taken in a clinic. Functional measures that a person can repeat - noticing night-vision difficulty, tracking contrast sensitivity between visits - add a continuous, real-world layer: how vision is actually working, day to day, in the interval between appointments. That layer can help a person describe changes more concretely and give a clinician a reason to look, or to look sooner. The two kinds of information are strongest together.

This is a screening signal, not a diagnosis. A contrast sensitivity result, or noticing that your night vision has changed, can be a reason to seek care - it cannot tell you whether you have retinitis pigmentosa or any other condition. RP is diagnosed and monitored by a retinal specialist using ERG, visual fields, OCT, and genetic testing. If you have a family history of RP, new difficulty seeing in the dark, or a narrowing sense of your side vision, please see an eye-care professional rather than drawing conclusions from any at-home measure.

What to do next

If night vision or dim-light comfort is the part of your sight that has changed, the single most useful thing you can do is get a proper eye examination - and, if there is a family history of inherited retinal disease, ask specifically whether a referral to a retinal specialist is appropriate. Bring concrete observations: how long you take to adjust to darkness, whether dusk driving has gotten harder, whether you are bumping into things at the edges of your vision.

You can also set a functional baseline for yourself. Take a free contrast sensitivity test to record where your contrast vision sits today. It takes a few minutes in a normally lit room, and a result you can repeat over time turns a vague sense of "things look flatter" into something you can point at and bring to your appointment. Think of it as one honest data point among several - a way to notice and describe change, and a complement to the clinical tests that do the actual diagnosing. Vision science is moving quickly on RP, from better imaging to gene-directed therapies, and the people best positioned to guide you through it are the specialists a clear, well-documented history helps you reach.